Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 287-304 , July 2008

Applying Neuroimaging Ligands to Study Major Depressive Disorder

  • Jeffrey H. Meyer, MD, PhD, FRCP(C)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jeffrey H. Meyer, MD, PhD, FRCP(C), Neurochemical Imaging Program in Mood Disorders, PET Centre, Department of Psychiatry and Centre for Addiction and Mental Health, University of Toronto, 250 College St, Toronto, ON M5T 1R8, Canada.

References 

  1. Meyer JH, McMain S, Kennedy SH, et al. Dysfunctional attitudes and 5-HT(2) receptors during depression and self-harm. Am J Psychiatry. 2003;160:90–99
  2. Meyer JH, McNeely HE, Sagrati S, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: An [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006;163:1594–1602
  3. Bhagwagar Z, Hinz R, Taylor M, et al. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: A positron emission study with [(11)C]MDL 100907. Am J Psychiatry. 2006;163:1580–1587
  4. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: Effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004;61:1271–1279
  5. Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12:4121–4125
  6. Cannon DM, Ichise M, Rollis D, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [(11)C]DASB; Comparison with bipolar disorder. Biol Psychiatry. 2007;62:870–877
  7. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63:1209–1216
  8. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375–1387
  9. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174–180
  10. Bhagwagar Z, Rabiner EA, Sargent PA, et al. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry. 2004;9:386–392
  11. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: A [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106–113
  12. Neumeister A, Bain E, Nugent AC, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004;24:589–591
  13. Lanzenberger RR, Mitterhauser M, Spindelegger C, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry. 2007;61:1081–1089
  14. Tauscher J, Bagby RM, Javanmard M, et al. Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: A [(11)C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry. 2001;158:1326–1328
  15. Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry. 2003;54:515–528
  16. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic. Nat Neurosci. 2007;10:1116–1124
  17. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843–1849
  18. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826–835
  19. Meyer JH, Goulding VS, Wilson AA, et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berlin). 2002;163:102–105
  20. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54:800–805
  21. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28:413–420
  22. Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003;60:386–391
  23. Kent JM, Coplan JD, Lombardo I, et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: A positron emission tomography study with 11C McN 5652. Psychopharmacology (Berlin). 2002;164:341–348
  24. Argyelan M, Szabo Z, Kanyo B, et al. Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study. J Affect Disord. 2005;89:115–123
  25. Rabiner EA, Bhagwagar Z, Gunn RN, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry. 2001;158:2080–2082
  26. Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5-HT(1A) receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol. 2000;27:509–513
  27. Martinez D, Hwang D, Mawlawi O, et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: A dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 2001;24:209–229
  28. Andree B, Thorberg SO, Halldin C, et al. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berlin). 1999;144:303–305
  29. Schildkraut JJ. and SS Kety, Biogenic amines and emotion. Science. 1967;156(771):21–37
  30. Mendels J, Frazer A. Brain biogenic amine depletion and mood. Arch Gen Psychiatry. 1974;30:447–451
  31. Young SN, Smith SE, Pihl RO, et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology. 1985;87:173–177
  32. Verhoeff NP, Kapur S, Hussey D, et al. A simple method to measure baseline occupancy of neostriatal dopamine d(2) receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology. 2001;25:213–223
  33. Carlsson A. The contribution of drug research to investigating the nature of endogenous depression. Pharmakopsychiatr Neuropsychopharmakol. 1976;9:2–10
  34. Mann JJ, Stanley M, McBride PA, et al. Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry. 1986;43:954–959
  35. Arora RC, Meltzer HY. Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry. 1989;146:730–736
  36. Arango V, Ernsberger P, Marzuk PM, et al. Autoradiographic demonstration of increased serotonin 5-HT2 and beta- adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry. 1990;47:1038–1047
  37. Yates M, Leake A, Candy JM, et al. 5HT2 receptor changes in major depression. Biol Psychiatry. 1990;27:489–496
  38. Hrdina PD, Demeter E, Vu TB, et al. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: Increase in 5-HT2 sites in cortex and amygdala. Brain Res. 1993;614:37–44
  39. Stockmeier CA, Dilley GE, Shapiro LA, et al. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology. 1997;16:162–173
  40. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res. 2003;37:357–373
  41. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 1997;17:8451–8458
  42. Klimek V, Schenck JE, Han H, et al. Dopaminergic abnormalities in amygdaloid nuclei in major depression: Apostmortem study. Biol Psychiatry. 2002;52:740–748
  43. Biegon A, Israeli M. Regionally selective increases in beta-adrenergic receptor density in the brains of suicide victims. Brain Res. 1988;442:199–203
  44. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818–825
  45. Maziere B, Crouzel C, Venet M, et al. Synthesis, Affinity and Specificity of 18F- Setoperone, a Potential Ligand for in-vivo Imaging of Cortical Serotonin Receptors. Nucl Med Biol. 1988;15(4):463–468
  46. Blin J, Sette G, Fiorelli M, et al. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J Neurochem. 1990;54:1744–1754
  47. Blin J, Pappata S, Kiyosawa M, et al. [18F] setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol. 1988;147:73–82
  48. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry. 1998;155:921–928
  49. Hinz R, Bhagwagar Z, Cowen PJ, et al. Validation of a tracer kinetic model for the quantification of 5-HT(2A) receptors in human brain with [(11)C]MDL 100,907. J Cereb Blood Flow Metab. 2007;27:161–172
  50. Lundkvist C, Halldin C, Ginovart N, et al. [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci. 1996;58:187–192
  51. Lopez-Gimenez JF, Vilaro MT, Palacios JM, et al. [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology. 1998;37:1147–1158
  52. Pinborg LH, Adams KH, Svarer C, et al. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab. 2003;23:985–996
  53. Lemaire C, Cantineau R, Guillaume M, et al. Fluorine-18-altanserin: A radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med. 1991;32:2266–2272
  54. Seeman P. Receptor Tables Vol. 2: Drug Dissociation Constants For Neuroreceptors and Transporters. Toronto: Schizophrenia Research; 1993;
  55. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 1983;1:214–216
  56. De Keyser J, Clayes A, DeBacker JP, et al. Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neuroscience Lett. 1988;91:142–147
  57. Johnson MP, Siegel BW, Carr AA. [3H]MDL 100,907: A novel selective 5-HT2A receptor ligand. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:205–209
  58. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268:1403–1410
  59. Leysen J. Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In:  Boulton A,  Baker G,  Jurio A editor. Drugs as Tools in Neurotransmitter Research (Neuromethods). Totowa, NJ: The Human Press; 1989;p. 299–349
  60. Fischman A, Bonab A, Babich J, et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent ziprasidone. J Pharmacol Exp Ther. 1996;279:939–947
  61. Ito H, Nyberg S, Halldin C, et al. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med. 1998;39:208–214
  62. Sadzot B, Lemaire C, Maquet P, et al. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab. 1995;15:787–797
  63. Biver F, Goldman S, Luxen A, et al. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. [see comments] Eur J Nucl Med. 1994;21:937–946
  64. Haugbol S, Pinborg LH, Arfan HM, et al. Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging. 2007;34:910–915
  65. Blin J, Crouzel C. Blood-cerebrospinal fluid and blood-brain barriers imaged by 18F-labeled metabolites of 18F-setoperone studied in humans using positron emission tomography. J Neurochem. 1992;58:2303–2310
  66. Price JC, Lopresti BJ, Meltzer CC, et al. Analyses of [(18)F]altanserin bolus injection PET data II: Consideration of radiolabeled metabolites in humans. Synapse. 2001;41:11–21
  67. Kapur S, Jones C, Da Silva J, et al. Reliability of [18F] setoperone in humans. Nucl Med Commun. 1997;18:395–399
  68. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci. 2007;32:86–102
  69. Stockmeier CA, Kellar KJ. In vivo regulation of the serotonin-2 receptor in rat brain. Life Sci. 1986;38:117–127
  70. Roth B, McLean S, Zhu X, et al. Characterization of two [3H]ketanserin recognition sites in rat striatum. J Neurochem. 1987;49:1833–1838
  71. O'Regan D, Kwok RP, PH Yu, et al. A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition. Psychopharmacology. 1987;92:42–47
  72. Todd KG, McManus DJ, Baker GB. Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain. Cell Mol Neurobiol. 1995;15:361–370
  73. D'Haenen H, Bossuyt A, Mertens J, et al. SPECT Imaging of serotonin2 receptors in depression psychiatry research. Neuroimaging. 1992;45:227–237
  74. Biver F, Wikler D, Lotstra F, et al. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br J Psychiatry. 1997;171:444–448
  75. Attar-Levy D, Martinot JL, Blin J, et al. The Cortical serotonin2 receptors studied with positron emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biological Psychiatry. 1999;45:180–186
  76. Meyer J, Kapur S, Houle S, et al. Prefrontal cortex 5-HT2 receptors in depression: A [18F] setoperone PET imaging study. Am J Psychiatry. 1999;156:1029–1034
  77. Meltzer C, Price J, Mathis C, et al. PET Imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psych. 1999;156:1871–1878
  78. Yatham LN, Liddle PF, Shiah IS, et al. Brain serotonin2 receptors in major depression: A positron emission tomography study. Arch Gen Psychiatry. 2000;57:850–858
  79. Messa C, Colombo C, Moresco RM, et al. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: A PET study. Psychopharmacology Berlin. 2003;167:72–78
  80. Mintun MA, Sheline YI, Moerlein SM, et al. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: In vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry. 2004;55:217–224
  81. Weissman A. The Dysfunctional Attitude Scale: A validation study. Diss Abstr Int. 1979;40:1389B–1390B
  82. First M, Spitzer R, Williams J, et al: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, Biometrics Research, 199
  83. Dohr K, Rush A, Bernstein I. Cognitive biases and depression. J Abn Psychol. 1989;98:263–267
  84. Simons AD, Garfield SL, Murphy GE. The process of change in cognitive therapy and pharmacotherapy for depression (Changes in mood and cognition). Arch Gen Psychiatry. 1984;41:45–51
  85. Cane D, Olinger L, Gotlib I, et al. Factor structure of the Dysfunctional Attitude Scale in a student population. J Clin Psychol. 1986;42:307–309
  86. Oliver J, Baumgart E. The Dysfunctional Attitude Scale: Psychometric properties and relation to depression in an unselected adult population. Cog Ther Res. 1985;9:161–167
  87. Raskin A, Friedman AS, aDiMascio A. Cognitive and performance deficits in depression. Psychopharmacol Bull. 1982;18:196–202
  88. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. (ed 2). New York: Oxford University Press; 1998;
  89. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303–312
  90. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease (Pathophysiologic and clinical implications). N Engl J Med. 1988;318:876–880
  91. Jellinger KA. Structural basis of dementia in neurodegenerative disorders. J Neural Transm Suppl. 1996;47:1–29
  92. Verhoeff N, Speelman J, Kuiper M, et al. Clinical significance of dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in patients with Parkinsonian syndromes. In:  De Deyn P, et al. editor. A Textbook of SPECT in Neurology and Psychiatry. London: John Libbey Publishers; 1997;p. 167–179
  93. Ehrin E, Farde L, de Paulis T, et al. Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: Preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot. 1985;36:269–273
  94. Farde L, Eriksson L, Blomquist G, et al. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET—a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9:696–708
  95. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993;6:602–608
  96. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab. 2000;20:423–451
  97. Volkow ND, Wang GJ, Fowler JS, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse. 1994;16:255–262
  98. Hume SP, Opacka-Juffry J, Myers R, et al. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse. 1995;21:45–53
  99. Endres CJ, Kolachana BS, Saunders RC, et al. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab. 1997;17:932–942
  100. Linnet K, Koed K, Wiborg O, et al. Serotonin depletion decreases serotonin transporter mRNA levels in rat brain. Brain Res. 1995;697:251–253
  101. Xiao Q, Pawlyk A, Tejani-Butt SM. Reserpine modulates serotonin transporter mRNA levels in the rat brain. Life Sci. 1999;64:63–68
  102. Yu A, Yang J, Pawlyk AC, et al. Acute depletion of serotonin down-regulates serotonin transporter mRNA in raphe neurons. Brain Res. 1995;688:209–212
  103. Benmansour S, Cecchi M, Morilak D, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density and mRNA level. J Neurosci. 1999;19:10494–10501
  104. Dewar KM, Grondin L, Carli M, et al. [3H]paroxetine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region following p-chlorophenylalanine and p-chloroamphetamine treatment. J Neurochem. 1992;58:250–257
  105. Graham D, Tahraoui L, Langer SZ. Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat. Neuropharmacology. 1987;26:1087–1092
  106. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol. 1996;298:27–30
  107. Han S, Rowell PP, Carr LA. D2 autoreceptors are not involved in the down-regulation of the striatal dopamine transporter caused by alpha-methyl-p-tyrosine. Res Commun Mol Pathol Pharmacol. 1999;104:331–338
  108. Ikawa K, Watanabe A, Kaneno S, et al. Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol. 1993;250:261–266
  109. Kilbourn MR, Sherman PS, Pisani T. Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol. 1992;216:109–112
  110. Lee CM, Javitch JA, Snyder SH. Recognition sites for norepinephrine uptake: Regulation by neurotransmitter. Science. 1983;220:626–629
  111. Bligh-Glover W, Kolli TN, Shapiro-Kulnane L, et al. The serotonin transporter in the midbrain of suicide victims with major depression. Biol Psychiatry. 2000;47:1015–1024
  112. Klimek V, Roberson G, Stockmeier CA, et al. Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression. J Psychiatr Res. 2003;37:387–397
  113. Perry EK, Marshall EF, Blessed G, et al. Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry. 1983;142:188–192
  114. Crow TJ, Cross AJ, Cooper SJ, et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology. 1984;23:1561–1569
  115. Mann JJ, Huang YY, Underwood MD, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. [see comments] Arch Gen Psychiatry. 2000;57:729–738
  116. Arango V, Underwood MD, Boldrini M, et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology. 2001;25:892–903
  117. Austin MC, Whitehead RE, Edgar CL, et al. Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience. 2002;114:807–815
  118. Hrdina P, Foy B, Hepner A, et al. Antidepressant binding sites in brain: Autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. J Pharm Exp Ther. 1990;252:410–418
  119. Lawrence KM, De Paermentier F, Cheetham SC, et al. Brain 5-HT uptake sites, labeled with [3H]paroxetine, in antidepressant-free depressed suicides. Brain Res. 1990;526:17–22
  120. Leake A, Fairbairn AF, McKeith IG, et al. Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res. 1991;39:155–165
  121. Little KY, McLauglin DP, Ranc J, et al. Serotonin transporter binding sites and mRNA levels in depressed persons committing suicide. Biol Psychiatry. 1997;41:1156–1164
  122. Hendricksen M, Thomas AJ, Ferrier IN, et al. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry. 2004;161:1096–1102
  123. Carroll FI, Kotian P, Dehghani A, et al. Cocaine and 3 beta-(4′-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues: New high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1995;38:379–388
  124. Laruelle M, Giddings SS, Zea-Ponce Y, et al. Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under “physiological” conditions. J Neurochem. 1994;62:978–986
  125. Shank RP, Vaught JL, Pelley KA, et al. McN-5652: A highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther. 1988;247:1032–1038
  126. Kung MP, Hou C, Oya S, et al. Characterization of [(123)I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur J Nucl Med. 1999;26:844–853
  127. Wilson A, Schmidt M, Ginovart N, et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: Synthesis, radiosynthesis, in vitro and ex vivo evaluation of [11C]-labeled 2-(phenylthio) araalkylamines. J Med Chem. 2000;43:3103–3110
  128. Wilson AA, Ginovart N, Hussey D, et al. In vitro and in vivo characterisation of [11C]-DASB: A probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol. 2002;29:509–515
  129. Choi SR, Hou C, Oya S, et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse. 2000;38:403–412
  130. Oya S, Choi SR, Hou C, et al. 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): An improved serotonin transporter ligand. Nucl Med Biol. 2000;27:249–254
  131. Pirker W, Asenbaum S, Kasper S, et al. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect. 1995;100:247–256
  132. Tauscher J, Pirker W, de Zwaan M, et al. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol. 1999;9:177–179
  133. Parsey RV, Kegeles LS, Hwang DR, et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med. 2000;41:1465–1477
  134. Ginovart N, Wilson AA, Meyer JH, et al. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse. 2003;47:123–133
  135. Erlandsson K, Sivananthan T, Lui D, et al. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: A SPECT validation study. Eur J Nucl Med Mol Imaging. 2005;32:1329–1336
  136. Brucke T, Kornhuber J, Angelberger P, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT (Binding kinetics in the human brain). J Neural Transm Gen Sect. 1993;94:137–146
  137. Kuikka JT, Bergstrom KA, Vanninen E, et al. Initial experience with single-photon emission tomography using iodine-123-labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane in human brain. Eur J Nucl Med. 1993;20:783–786
  138. Ikoma Y, Suhara T, Toyama H, et al. Quantitative analysis for estimating binding potential of the brain serotonin transporter with [11 C]McN5652. J Cereb Blood Flow Metab. 2002;22:490–501
  139. Buck A, Gucker PM, Schonbachler RD, et al. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: Assessment of methods. J Cereb Blood Flow Metab. 2000;20:253–262
  140. Ginovart N, Wilson AA, Meyer JH, et al. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: Modeling strategies. J Cereb Blood Flow Metab. 2001;21:1342–1353
  141. Houle S, Ginovart N, Hussey D, et al. Imaging the serotonin transporter with positron emission tomography: Initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med. 2000;27:1719–1722
  142. Ichise M, Liow JS, Lu JQ, et al. Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096–1112
  143. Catafau AM, Perez V, Penengo MM, et al. SPECT of serotonin transporters using 123I-ADAM: Optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med. 2005;46:1301–1309
  144. Frankle WG, Lombardo I, New AS, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: A positron emission study with [11C]McN 5652. Am J Psychiatry. 2005;162:915–923
  145. Praschak-Rieder N, Wilson AA, Hussey D, et al. Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol Psychiatry. 2005;58:825–830
  146. Malison RT, Price LH, Berman R, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. [see comments] Biol Psychiatry. 1998;44:1090–1098
  147. Ichimiya T, Suhara T, Sudo Y, et al. Serotonin transporter binding in patients with mood disorders: A PET study with [11C](+)McN5652. Biol Psychiatry. 2002;51:715–722
  148. Newberg AB, Amsterdam JD, Wintering N, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med. 2005;46:973–977
  149. Parsey RV, Hastings RS, Oquendo MA, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry. 2006;163:52–58
  150. Herold N, Uebelhack K, Franke L, et al. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [(123)I]-ADAM. J Neural Transm. 2006;113:659–670
  151. Talbot PS, Frankle WG, Hwang DR, et al. Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse. 2005;55:164–175
  152. Kuikka JT, Bergstrom KA, Ahonen A, et al. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med. 1995;22:356–360
  153. Wilson AA, DaSilva JN, Houle S. In vivo evaluation of [11C]- and [18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. Nucl Med Biol. 1996;23:141–146
  154. Kung HF, Kim HJ, Kung MP, et al. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med. 1996;23:1527–1530
  155. De Keyser J, De Backer JP, Ebinger G, et al. [3H]GBR 12935 binding to dopamine uptake sites in the human brain. J Neurochem. 1989;53:1400–1404
  156. Marcusson J, Eriksson K. [3H]GBR-12935 binding to dopamine uptake sites in the human brain. Brain Res. 1988;457:122–129
  157. Cortes R, Soriano E, Pazos A, et al. Autoradiography of antidepressant binding sites in the human brain: Localization using [3H]imipramine and [3H]paroxetine. Neuroscience. 1988;27:473–496
  158. Gurevich EV, Joyce JN. Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology. 1996;14:309–323
  159. Jucaite A, Odano I, Olsson H, et al. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study. Eur J Nucl Med Mol Imaging. 2006;33:657–668
  160. Chalon S, Garreau L, Emond P, et al. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther. 1999;291:648–654
  161. Emond P, Garreau L, Chalon S, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3′,4′-disubstituted phenyl)nortropane: New high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40(9):1366–1372
  162. Shetty HU, Zoghbi SS, Liow JS, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I. Eur J Nucl Med Mol Imaging. 2007;34:667–678
  163. Neumeister A, Willeit M, Praschak-Rieder N, et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med. 2001;31:1467–1473
  164. Sarchiapone M, Carli V, Camardese G, et al. Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res. 2006;147:243–248
  165. Brunswick DJ, Amsterdam JD, Mozley PD, et al. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry. 2003;160:1836–1841
  166. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry. 1998;155:344–349
  167. Pal P, Lee C, Samii A, et al. Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki. Parkinsonism Relat Dis. 2001;7:305–309
  168. Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000;57:470–475
  169. Nomikos GG, Damsma G, Wenkstern D, et al. In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse. 1990;6:106–112
  170. Zhu MY, Klimek V, Dilley GE, et al. Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry. 1999;46:1275–1286
  171. Boldrini M, Underwood MD, Mann JJ, et al. More tryptophan hydroxylase in the brainstem dorsal raphe nucleus in depressed suicides. Brain Res. 2005;1041:19–28
  172. Bonkale WL, Murdock S, Janosky JE, et al. Normal levels of tryptophan hydroxylase immunoreactivity in the dorsal raphe of depressed suicide victims. J Neurochem. 2004;88:958–964
  173. Agren H, Reibring L. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry. 1994;27:2–6
  174. Rosa-Neto P, Diksic M, Okazawa H, et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry. 2004;61:556–563
  175. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behaviour. Annu Rev Neurosci. 1999;22:197–217
  176. Grote SS, Moses SG, Robins E, et al. A study of selected catecholamine metabolizing enzymes: A comparison of depressive suicides and alcoholic suicides with controls. J Neurochem. 1974;23:791–802
  177. Gottfries CG, Oreland L, Wiberg A, et al. Lowered monoamine oxidase activity in brains from alcoholic suicides. J Neurochem. 1975;25:667–673
  178. Mann JJ, Stanley M. Postmortem monoamine oxidase enzyme kinetics in the frontal cortex of suicide victims and controls. Acta Psychiatr Scand. 1984;69:135–139
  179. Sherif F, Marcusson J, Oreland L. Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims. Eur Arch Psychiatry Clin Neurosci. 1991;241:139–144
  180. Ordway GA, Farley JT, Dilley GE, et al. Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res. 1999;847:71–79
  181. Galva MD, Bondiolotti GP, Olasmaa M, et al. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex. J Neural Transm Gen Sect. 1995;101:83–94
  182. Hasselbalch SG, Madsen K, Svarer C, et al: Reduced 5-HT(2A) receptor binding in patients with mild cognitive impairment. Neurobiol Aging, in press
  183. Krishnan KR. Biological risk factors in late life depression. Biol Psychiatry. 2002;52:185–192
  184. Rajkowska G, Miguel-Hidalgo JJ, Dubey P, et al. Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biol Psychiatry. 2005;58:297–306
  185. Smith GS, Gunning-Dixon FM, Lotrich FE, et al. Translational research in late-life mood disorders: Implications for future intervention and prevention research. Neuropsychopharmacology. 2007;32:1857–1875
  186. Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A. 1996;93:14065–14069
  187. Fowler JS, Logan J, Ding YS, et al. Non-MAO A binding of clorgyline in white matter in human brain. J Neurochem. 2001;79:1039–1046
  188. Bergstrom M, Westerberg G, Nemeth G, et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography. Eur J Clin Pharmacol. 1997;52:121–128
  189. Bottlaender M, Dolle F, Guenther I, et al. Mapping the cerebral monoamine oxidase type A: Positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone. J Pharmacol Exp Ther. 2003;305:467–473
  190. Ginovart N, Meyer JH, Boovariwala A, et al. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab. 2006;26:330–344
  191. Dolle F, Valette H, Bramoulle Y, et al. Synthesis and in vivo imaging properties of [11C]befloxatone: A novel highly potent positron emission tomography ligand for mono-amine oxidase-A. Bioorg Med Chem Lett. 2003;13:1771–1775
  192. Bergstrom M, Westerberg G, Langstrom B. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies. Nucl Med Biol. 1997;24:287–293
  193. Tweedie DJ, Burke MD. Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice (Identification and quantitation of two novel harmine metabolites). Drug Metab Dispos. 1987;15:74–81
  194. Taylor BP, Bruder GE, Stewart JW, et al. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006;163:73–78
  195. Rabiner EA, Messa C, Sargent PA, et al. A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: Normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage. 2002;15:620–632
  196. Baxter LR, Phelps ME, Mazziotta JC, et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorder A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987;44:211–218
  197. Baxter LR, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989;46:243–250
  198. Mayberg HS, Lewis PJ, Regenold W, et al. Paralimbic hypoperfusion in unipolar depression. J Nucl Med. 1994;35:929–934
  199. Bench CJ, Friston KJ, Brown RG, et al. The anatomy of melancholia—focal abnormalities of cerebral blood flow in major depression. Psychol Med. 1992;22:607–615
  200. Drevets WC, Videen TO, Price JL, et al. A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628–3641
  201. Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824–827
  202. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675–682
  203. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: A potential predictor of treatment response. Neuroreport. 1997;8:1057–1061
  204. Langenecker SA, Kennedy SE, Guidotti LM, et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry. 2007;
  205. Fu CH, Mourao-Miranda J, Costafreda SG, et al. Pattern Classification of sad facial processing: Toward the development of neurobiological markers in depression. Biol Psychiatry. 2007;63:656–662
  206. Heinz A, Braus DF, Smolka MN, et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci. 2005;8:20–21
  207. Hariri AR, Drabant EM, Munoz KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry. 2005;62:146–152
  208. Smith GS, Lotrich FE, Malhotra AK, et al. Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology. 2004;29:2226–2234
  209. Voineskos AN, Wilson AA, Boovariwala A, et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berlin). 2007;193:539–545
  210. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249–258
  211. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry. 2001;62(suppl 15):12–17
  212. Thase ME. Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence. CNS Spectr. 2004;9:808-16–818-21
  213. First M, Spitzer R, Williams J, et al. Structured Clinical Interview for DSM-IV-Non-Patient Edition (SCID-NP, Version 1.0). Washington, DC: American Psychiatric Press; 1995;
  214. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305–1322
  215. Wilson AA, Johnson DP, Mozley D, et al. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol. 2003;30:85–92
  216. Ding YS, Lin KS, Garza V, et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse. 2003;50:345–352
  217. Logan J, Wang GJ, Telang F, et al. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: Problems and progress. Nucl Med Biol. 2007;34:667–679
  218. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34:13–25
  219. DaSilva JN, Lourenco CM, Meyer JH, et al. Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:1680–1683
  220. Giovacchini G, Chang MC, Channing MA, et al. Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography. J Cereb Blood Flow Metab. 2002;22:1453–1462
  221. Matsumoto K, Imahori Y, Fujii R, et al. Evaluation of phosphoinositide turnover on ischemic human brain with 1-[1-11C]-butyryl-2-palmitoyl-rac-glycerol using PET. J Nucl Med. 1999;40:1590–1594
  222. Martarello L, Kilts CD, Ely T, et al. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl Med Biol. 2001;28:187–195
  223. Vasdev N, Garcia A, Stableford WT, et al. Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): A radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. Bioorg Med Chem Lett. 2005;15:5270–5273

 Neurochemical Imaging Program in Mood Disorders, PET Centre, Department of Psychiatry and Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada.

PII: S0001-2998(08)00030-5

doi: 10.1053/j.semnuclmed.2008.02.007

Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 287-304 , July 2008

Article Tools

* Image Usage & Resolution